UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-Q __________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value per share BLUE The NASDAQ Stock Market LLC FORM 10-Q __________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ...

Financial Data and Key Metrics Changes - The company has made significant adjustments to its operating plan, removing over $500 million from its operating budget through mid-2022, which extends its financial runway while maintaining core programs [10][20][24] - The revised operating plan aims to balance innovation with financial sustainability, focusing on delivering core programs by 2022 and securing non-dilutive funding [20][21] Business Line Data and Key Metrics Changes - The company submitted a US Biologics License Application (BLA) for ide-cel for late-stage multiple myeloma treatment, with plans for a data presentation at the virtual ASCO meeting [8][18] - For sickle cell disease, the company reached alignment with the FDA on an accelerated approval path for LentiGlobin, planning to file for approval in the second half of 2021 [9][17] Market Data and Key Metrics Changes - The company is actively engaging with European authorities for the sickle cell opportunity, aiming to ensure access to data and finalize requirements for regulatory approval [66] - The company anticipates the first commercial patients for ZYNTEGLO in Germany later this year, with ongoing reimbursement discussions in other EU markets [70] Company Strategy and Development Direction - The company is focused on delivering transformative products while maintaining a strong operational foundation, emphasizing the importance of culture and innovation [11][20] - The revised collaboration with Bristol-Myers Squibb (BMS) includes a $200 million non-dilutive funding agreement, enhancing operational flexibility and aligning manufacturing responsibilities [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the challenges posed by the COVID-19 pandemic, highlighting the resilience and adaptability of the team [7][12] - The company remains committed to its long-term vision while adapting to the current economic landscape, ensuring that core values and innovation are preserved [11][20] Other Important Information - The company plans to present updated clinical data for Lenti-D for CALD at a medical meeting later this year, with regulatory filings in the EU planned for this year and in the US next year [19] - The company is prioritizing the core four late-stage programs while optimizing operational resources to ensure sustainability [20][24] Q&A Session Summary Question: What does "general agreement" mean regarding the sickle cell path? - Management clarified that "general agreement" refers to a legal categorization and does not change the agreements with the FDA, confirming that the filing will be based on HGB-206 data, not HGB-210 [28][29] Question: How does the $200 million correlate with the ex-US opportunity for bb2121? - Management expressed confidence that the deal reflects significant value and aligns operational responsibilities, ensuring a sensible split of resources [32][34] Question: What are the gating items on manufacturing related to FDA for sickle cell? - Management indicated that clinical alignment and manufacturing transitions are well underway, with ongoing discussions to ensure readiness for regulatory timelines [48][50] Question: Why is HGB-210 necessary as a post-approval confirmatory study? - Management explained that HGB-210 serves as a classic post-approval confirmatory trial to provide additional follow-up data for full approval [58] Question: What is the expected timeline for the sickle cell filing? - Management anticipates submitting the BLA in the second half of 2021, with a focus on complete resolution of severe vaso-occlusive events as the primary endpoint [17][55]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-Q __________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ___________________________________________________________________________ FORM 10-K ___________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...